Diabetes
Read Time: 15 mins

Indian Phenotype Characteristics Among Patients with Type 2 Diabetes Mellitus: Insights from a Non-interventional Nationwide Registry in India

Published Online: May 26th 2022 touchREVIEWS in Endocrinology. 2022;18(1):63–70 DOI: https://doi.org/10.17925/EE.2022.18.1.63
Authors: Sanjay Kalra, Ambrish Mithal, Abdul Hamid Zargar, Bipin Sethi, Mala Dharmalingam, Sujoy Ghosh, Ranjini Sen
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Background: Indian patients with type 2 diabetes mellitus (T2D) constitute one-sixth of affected adults globally. Here, we evaluate the association of body mass index (BMI) with body fat percentage (BF%) and glycated haemoglobin (HbA1c) levels among patients with T2D in India. Method: This was a cross-sectional Indian registry study across 845 geographically diverse zones between December 2017 and August 2019. Results: Of 37,927 patients, 55.6% were men, with a mean ± standard deviation age of 54.2 ± 11.5 years and HbA1c of 8.3 ± 1.71%. Mean ± standard deviation BMI and BF% were 27.0 ± 4.6 kg/m2 and 32.0 ± 8.0%, respectively. Overall, 15.4% of patients were overweight, and 25.0% were obese. Despite fewer males (20.7%) having BMI-based obesity than females (31.2%), around three-quarters of both sexes had BF%-defined obesity (males 77.2%; females 71.2%). One-third of males (34.6%) and 41.9% of females had BF%-defined obesity despite normal BMI. The association was substantiated by a moderately significant correlation (r=0.51) between BMI and BF% in the overall population (p<0.0001). Conclusion: This pan-India registry presents a real-world reflection of the Asian Indian phenotype: high BF% despite lower BMI in people with T2D. This highlights the importance of primordial and primary prevention, and may guide decisions on the choice of agents for glycaemic control, with a preference for drugs that promote weight loss or are weight neutral.

Keywords

Body fat percentage, body mass index, glycated haemoglobin A, obesity, overweight, type 2 diabetes mellitus

Article:

The pandemic of type 2 diabetes mellitus (T2D) is a growing concern, especially in low- and middle-income countries, which contribute to nearly 75% of the disease burden.1 Indian patients with T2D constitute 1 in 6 adults with T2D globally, with marked differences in prevalence across the states.2,3 The younger age of onset and faster progression from prediabetes to diabetes among Indians increases the disease burden.4 With a 10.4% age-adjusted comparative prevalence of T2D, India accounts for the highest mortality in the Southeast Asian region, with 1,010,262 deaths due to T2D in 2019.2,5 The age-standardized disability-adjusted life year rate for T2D increased in India by 39.6% (95% uncertainty interval [UI] 32.1– 46.7%) from 1990 to 2016.5 Notably, of patients who died due to T2D in India in 2016, 42.6% (95% UI 41.6– 43.9%) were younger than 70 years.5 Nearly half (47.3%) of the patients diagnosed with diabetes had not been diagnosed previously.6

Although the prevalence of T2D remains higher in the economically advanced states in India, it has surged rapidly in the less-developed states.5 Rapid epidemiological transition with an ageing population, compounded by modifiable risk factors such as an unhealthy diet, sedentary lifestyle, tobacco use and obesity, is an important driver of the T2D epidemic in India.5 Among these, obesity is one of the most pivotal and dominant risk factors; prevalence of overweight in India markedly increased from 9.0% in 1990 to 20.4% in 2016.5 Anthropometric analysis from the National Family Health Survey III and IV highlighted a rising prevalence of overweight/obesity across urban and rural locations – the prevalence among men and women was observed to be 38.4% and 36.2%, respectively.7 A systematic review reported that more than 135 million individuals are affected by obesity in India, with variations in prevalence rates of obesity and central obesity (11.8–31.3% and 16.9–36.3%, respectively).8 It is estimated that the percentage of overweight people will more than double and obesity will triple among Indian adults between 2010 and 2040.9 Excessive accumulation of visceral fat causes an imbalance in endocrine function and release of proinflammatory factors, which results in the development of insulin resistance, T2D and other poor cardiometabolic outcomes.10,11

The Asian Indian phenotype (IP) is characterized by unique clinical and biochemical abnormalities, including increased insulin resistance and greater abdominal adiposity (i.e. higher waist circumference and waist-to-hip ratio), despite lower body mass index (BMI), lower adiponectin and higher high-sensitivity C-reactive protein levels. These, together with the dyslipidaemia triad – low high-density lipoprotein (HDL), high low-density lipoprotein (LDL) and high triglycerides – make Indians more prone to developing T2D.12,13 South Asians tend to have a higher body fat percentage (BF%) compared with other ethnicities, despite lower BMI values – commonly referred to as the Yajnik and Yudnik (Y-Y) paradox.14,15 Evaluating the body composition in terms of BF% in patients with T2D can identify risk factors, facilitating early prevention and reducing complications. Additionally, because of the heterogeneity of T2D among the states in India, it is vital to understand the link between risk factors and BF%. Previous studies from India have explored the relationship between BMI and BF%; however, there are gaps in evidence, as the studies had a limited sample size.16–23 In this regard, large-scale registries can provide robust data on IP attributes in people with diabetes.

This multistate IP registry aimed to evaluate the BF% across various BMI categories in patients with T2D in India. As secondary objectives, the study aimed to analyse patient characteristics, correlate glycated haemoglobin (HbA1c) levels with various BMI categories, record associated comorbidities, and document use of on-going glucose-lowering drugs.

Methods

Study design and setting

We conducted this non-interventional, multicentre, cross-sectional study across 845 study centres from geographically diverse zones of India, encompassing different tiers of healthcare centres and investigators (general practitioners and specialists in diabetes management) between 11 December 2017 and 8 August 2019. Participants were randomly recruited across India, without any distinct zone variation, predominantly from the urban centres. The study was initiated at each site after ethics committee approval, and was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice, and Good Pharmacoepidemiology Practice guidelines. All patients provided written informed consent for participation before enrolment during their routine clinic visits. Adults (≥18 years old) with previously diagnosed T2D with an HbA1c report available within the 3 months prior to screening were included in the registry. Patients with type 1 diabetes, pancreatic diabetes or secondary diabetes were excluded. No study medication was prescribed or administered as part of study procedures.

Data collection and data variables

Information was collected on demographics (age, sex, history of tobacco use), anthropometry (weight, height, waist and hip circumference), clinical characteristics (vital signs, duration of T2D, comorbidities such as hypertension, dyslipidaemia, chronic kidney disease, cardiovascular disease [CVD], heart failure, stroke/transient ischaemic attack, neuropathy, retinopathy), HbA1c and anti-diabetic/concomitant medications. T2D was defined as HbA1c >6.5% and fasting blood glucose >120 mg/dL. Body fat analysis included total body fat content and distribution, measured using a validated Omron fat analyzer (model HBF-212; Omron Healthcare India Pvt. Ltd., Gurugram, Haryana, India). In addition to weight, it also measured the BF%, visceral fat level and BMI. Asian Indian cut-off values for defining obesity were used in this study; operational definitions of data variables are presented in Table 1.15,19–21 Normal weight obesity (NWO) was defined as having normal body weight but with a high BF%, and leads to some of the same health risks as obesity; metabolically obese patients with normal weight were defined as those with normal weight and BMI, but displaying some metabolic characteristics that increase the risk of developing metabolic syndrome in the same way as obesity.

Statistical analysis

The patient characteristics and variables were described using frequency distributions and proportions for categorical variables. Continuous variables were described using mean ± standard deviation (SD). To understand the effect of sex, subgroup analysis for males and females was conducted for anthropometric variables. Correlation between BF% and BMI was evaluated using the Pearson correlation coefficient (r). Statistical analyses were performed with statistical software, SAS® 9.4 (SAS Institute Inc., Cary, NC, USA), and a p value of <0.05 was considered statistically significant.

Results

Of 38,849 subjects with T2D enrolled in the registry, 37,927 were considered for the final analysis after excluding extreme or erroneous values.

Sociodemographic characteristics

The mean age of patients was 54.2 ± 11.5 years; 54.9% (n=20,805) were aged 40–59 years and about one third (34.4%, n=13,054) were aged ≥60 years. More than half (55.6%; n=21,098) were men, and approximately 13.8% (n=5,228) were current tobacco users. In all, 67.4% (n=25,577) of patients had a medical/surgical history, of which hypertension (71.3%, n=18,225) and dyslipidaemia (50.4%, n=12,887) were most common. Furthermore, CVD and neuropathy were reported in 9.2% (n=2,347) and 9.4% (n=2,393) of patients, respectively (Table 2). The proportion of patients on concomitant medications was as follows: angiotensin II antagonists (47.6%, n=12,871), beta-blockers (14.8%, n=4,012), calcium channel blockers (21.2%, n=5,725), antithrombotic agents (16.3%, n=4,404) and lipid-modifying agents (55.2%, n=14,947; primarily atorvastatin and rosuvastatin [data not shown]).

Anthropometric and clinical characteristics

Table 3 shows the anthropometric and clinical characteristics of the study population.19 The mean body weight and height of enrolled subjects were 72.0 ± 13.0 kg and 161.5 ± 9.1 cm, respectively. The mean BMI was 27.0 ± 4.6 kg/m2, while the mean BF% was 32.0 ± 8.0%. Mean visceral fat percentage was 13.0 ± 6.5%. The mean waist and hip circumferences were 95.2 ± 10.5 cm and 100.5 ± 10.2 cm, respectively. Overall, 83.9% (n=31,828) of the study population had BMI above the normal range. About 15.4% (n=5,851) and 43.5% (n=16,508) were overweight and pre-obese as per BMI, respectively. One quarter (n=9,469) of the enrolled patients were obese, of which most (94.1%, n=8,917) were type 1 obese and 5.6% (n=534) were type 2 obese. Notably, despite a comparable mean BMI in both sexes, the mean BF% was higher among females (35 ± 7.8%) than males (29 ± 7.0%). Data on vital signs showed a mean systolic blood pressure of 131.3 ± 15.0 mmHg, diastolic blood pressure of 81.1 ± 8.4 mmHg and mean heart rate of 81.7 ± 9.80 beats per minute.

Diabetes-related measures

The mean duration of diabetes was 78.2 ± 72.1 months, with more than half of patients (52.7%, n=20, 009) having diabetes for >5 years. Overall, the mean HbA1c was 8.3 ± 1.7%, with a similar distribution across both sexes. Most patients (99.0%, n=37,536) were taking an on-going anti-diabetic medication. Among all anti-diabetic medications, metformin monotherapy (97.9%, n=36,748) was the most commonly prescribed, followed by glimepiride (53.1%, n=19,944). Some patients were receiving newer anti-diabetic medications, such as sodium–glucose co-transporter-2 inhibitors (SGLT2is; dapagliflozin 16.2% [n=6,076], empagliflozin 4.2% [n=1,592]) and dipeptidyl peptidase-4 inhibitors (DPP4is; teneligliptin 25.5% [n=9,578] and sitagliptin 11.5% [n=4,298]). In addition, 15.8% (n=5,918) were receiving insulin and analogues (data not shown).

Body fat content and body mass index categories

Among people with an underweight (2.7%, n=299) or normal BMI (13.3%, n=5,055), the mean BF% was 20.1% and 25.6%, respectively. Among people who were overweight (15.4%, n=5,851), pre-obese (43.5%, n=16,508) and obese (25.0%, n=9,469), the mean BF% was 28.8%, 32.1% and 37.3%, respectively.

Sex-stratified subgroup analysis

The sex-stratified analysis revealed cases of NWO (BMI within the normal range and a high BF%). The subgroup analysis of males (n=21,098) revealed that, although 20.7% (n=4,369) had an obese BMI (most were type 1 obese), more than three- quarters (77.2%, n=16,285) had an obese BF%. Despite having a low BMI (underweight category, n=202), 22.3% (n=45) were obese as per their BF% (Table 4A).19 Similarly, more than one-third (34.6%, n=1,142) of males with normal BMI (n=3,299) and 66.3% (n=2,469) with an overweight BMI (n=3,722) had an obese BF%. Furthermore, nearly one quarter (23.8%; n=48) of males with an underweight BMI and more than half (53.3%, n=1,760) with a normal BMI had a relatively higher BF%, which was in the ‘acceptable’ category. Conversely, 12.6% (n=1,225) of males with a pre-obese BMI and 2.4% (n=234) with an obese BMI had a normal BF% (range 2–24%).

Likewise, among females (n=16,827), 31.2% (n=5,249) had obesity per their BMI; however, a higher proportion (71.8%, n=12,085) were classified as obese per their BF%. Among females with an underweight (n=110) and normal (n=2,000) BMI, 11.8% (n=13) and 41.9% (n=837), respectively, had an obese BF%. Most (62.2%, n=1,425) females with an overweight BMI were classified obese. Moreover, 27.3% (n=30) with an underweight BMI and 26.2% (n=524) with a normal BMI had a BF% of 25–31%, resulting in them being grouped in the ‘acceptable’ category (Table 4B).19 Figure 1 characterizes IP among individuals with a normal, overweight or pre-obese BMI, with a BF% in ‘acceptable’ or ‘obese’ category. Conversely, 27.6% of females (n=1,952) with a pre-obese BMI and 9.8% (n=514) with an obese BMI had a normal BF% (range 10–31%).

Correlation between body fat percentage and body mass index

A statistically significant, moderate positive correlation (r=0.51; p<0.0001) between BF% and BMI was seen in the overall population. Similar findings were reflected for both males and females, with a significant positive relationship between BF% and BMI in both groups (Figure 2). The scatter plot illustrates that even patients at the lower end of the spectrum of BMI tend to have a high BF%.

Correlation between glycated haemoglobin level and body mass index categories

Among the patients with HbA1c <7.0%, nearly one quarter (24.9%, n=2,144) were obese, while 44.6% (n=3,835) were pre-obese (Table 5).19 Similar trends were observed for higher HbA1c levels; among patients with high HbA1c levels (≥7.0), the proportion of obese patients ranged from 25.0% to 26.1%, while that for pre-obese patients ranged from 43.0% to 45.4% (Table 5). However, the correlation analysis did not demonstrate any relationship between HbA1c level and BMI (Supplementary Figure 1).

Body fat content with increasing age and diabetes duration

The sex-stratified subgroup analysis among males and females showed a significant association between BF% and age (Supplementary Table 1). Most males with an obese BF% were aged >60 years; most female subjects with an obese BF% were aged 50–59 years. Similarly, a strong significant association was found between BF% and duration of diabetes (p<0.05) in both sexes. Most males and females with an obese BF% had a duration of diabetes between 10 and 20 years (Supplementary Table 2).

Discussion

This pan-India registry presents a comprehensive real-world reflection of the IP in patients with T2D. The study validates that Indians have a high BF%, despite having relatively lower BMI. Among the patients with normal BMI, many had an obese BF% despite using the Asia-specific BMI cut off, which is lower than that used for Caucasians.22 Of these patients with NWO, more females had an obese BF% than males. The correlation coefficient revealed a moderate positive relation between BMI and BF% in both males and females. Overall, the most prevalent comorbidities were hypertension and dyslipidaemia. Although most were taking on-going anti-diabetic medications, the mean HbA1c levels were higher than those recommended by the American Diabetes Association guidelines.21 There was a similar distribution of individuals with an obese and pre-obese BMI across HbA1c categories.

This study provides robust evidence confirming one of the crucial traits of the IP, which is NWO encompassing high BF% despite lower BMI among males and females. Among the patients with normal BMI, one-third of both sexes had an obese BF%, and among patients with a pre-obese BMI, more than two-thirds had an obese BF%. The relationship was further substantiated by a statistically significant positive correlation between BMI and BF%. Generally, in South Asians compared with Caucasians, BF% is 3–5 percentage points higher for the same BMI, and BMI is 3–4 units lower.22,23 South Asians tend to have earlier onset of diabetes, a longer duration of diabetes, lower BMI, lower waist circumference, lower HDL, but relatively higher triglycerides and HbA1c when compared with white Europeans.24 A study among young, healthy male adults in Indonesia revealed that insulin resistance is more strongly correlated with BF%, visceral fat and body weight than with BMI and waist circumference.25 Bhopal postulated a four-stage model explaining the higher risk of T2D in South Asian compared with European populations.26 In South Asians compared with Europeans: (1) at birth, babies are smaller, have lower adipose and lower lean mass; (2) in childhood and early adulthood, excess calorie intake deposits preferentially in the upper body and ectopic fat stores (rather than lower body or as superficial subcutaneous fat); (3) a vicious cycle of high levels of plasma insulin, triglycerides and glucose, and a fatty liver appears, exacerbated by low physical activity and excess calories; (4) pancreatic β cells fail due to fewer β cells at birth, exposure to apoptotic triggers such as fat in the pancreas, and high demand from insulin resistance.26

A study from Sri Lanka demonstrated a significant positive correlation between BMI and BF% in males (r=0.75, p<0.01) and females (r=0.82, p<0.01) of all ages.27 The paradox of low BMI and high BF% was starkly reported for Indians in Singapore, with Indians having the highest BF% among a mixed population of Indian, Chinese and Malayan people.28 NWO is an under-recognized arena; however, evidence on its pathophysiology and its association with metabolic diseases such as T2D, hypertension and dyslipidaemia is evolving.29 Results from the Kerala Diabetes Prevention Program demonstrated that about one-third of the study subjects had NWO.30 The study also reported a significantly higher proportion of individuals with T2D, hypertension and dyslipidaemia in the NWO group compared with the non-obese group.30 NWO was also identified as an independent strong predictor of cardiovascular mortality, and a widely prevalent problem in individuals of Asian descent.29 A study among males in Lucknow reported that 44.0% of subjects showed a high BF% (>25%) with a BMI of 24.0–24.9 kg/m2, and 4.7% at a lower BMI
(<20 kg/m2). Rates of high BF% in the BMI range 20–21.9 kg/m2 and 22–23.9 kg/m2 were 9.5% and 18.4%, respectively. In addition, BMI was highly correlated with BF% (r=0.73, p<0.001).17

The study results demonstrate that females have a proportionally higher BF% than males, despite having similar BMI. A real-world study including data from the Korea National Health and Nutrition Examination Survey (2007–2010) revealed that whole BF% content was higher in women than in men.31 This study also demonstrated that the average BMI and whole BF% content of women were higher than those of men; however; the average waist circumference at the time of diabetes diagnosis was similar (approximately 88 cm) in both sexes.31 Similarly to our results, a community-based study involving 1,080 adult participants from Haryana, India, reported a comparable mean BMI between males and females, but with a higher mean BF% in females (28.69%) than in males (26.02%). The study further showed a strong positive correlation between BMI and BF% (r=0.747, p<0.001) in the overall population.32

A cross-sectional study among non-pregnant women from Haryana revealed that women with underweight and normal BMI, had mean (SD) BF% of 23.8% (4.1) and 31.0% (5.0), respectively. Also, there was a strong positive relation between BMI and BF% (r=0.85, p<0.001).32 A study among adolescents (aged 10–14 years) in Dibrugarh, India, showed that of the participants with normal BMI, 9% were overweight and 1% were obese under the BF% criteria. In addition, BMI and BF% had a significant positive correlation (r=0.70, p<0.001).33 According to the thrifty genotype hypothesis, the predisposition to diabetes must have evolved as an adaptive trait in certain environmental situations, which later turned disadvantageous because of the changes in lifestyle.34 Early prevention or treatment of childhood obesity focusing on lifestyle factors may be critical for preventing diabetes in South Asians. Chooi et al. evaluated the effects of diet-induced 5% weight loss on body composition in metabolically obese normal-weight Asians, and revealed that weight loss decreases total fat mass by ~9% and intrahepatic fat by ~50% (p<0.05). Fasting plasma insulin and cardiometabolic factors, such as triglyceride and LDL, HDL and total cholesterol concentrations, were also reduced (p<0.05). Additionally, insulin sensitivity indices increased by 21% to 26% (both p< 0.05).35

More than half of this study’s patients were aged 40–60 years. Diabetes occurs at a younger age and a lower BMI in South Asians compared to Caucasians, raising the risk of cardiovascular and renal complications.36 A registry including data from Singapore (including Indians) elucidated that diabetes was three times more common in Southeast Asians compared with white patients with heart failure, despite younger age and less obesity.37 Interestingly, ethnic differences in T2D risk between South Asians originate in childhood. A study of 4,633 children (9- to 10-year-olds) of South Asian, black African-Caribbean and white European origin, reported that South Asian children showed stronger associations with adiposity, insulin resistance and HbA1c than white Europeans. Fat mass was positively associated with HbA1c in South Asians and black African-Caribbeans, but not in white Europeans; for a 1×SD increase in fat mass percentage, percentage differences in HbA1c were 0.04% (95% confidence interval [CI]: 0.03–0.06), 0.04% (95% CI 0.02–0.05) and 0.02% (95% CI -0.00–0.04), respectively (p interaction <0.001).38

BF% is a crucial element in predicting T2D, with marked differences between sexes. A study from India revealed that despite an insignificant correlation between HbA1c levels and BMI, there was a significant positive correlation between HbA1c and fat mass (r=0.452, p<0.001) in patients with T2D.16 In addition, a prospective study from India also reported that centrally and peripherally obese subjects with dyslipidaemia had a significant association with HbA1c in T2D.39 A community-based Korean cohort study demonstrated that, compared with people with a lower BF% (quintile 1), the risk for T2D significantly increased among those with a higher BF% (22.8% in men and 32.9% in women; ≥ quintile 4).40 However, our study showed a similar distribution for obese and pre-obese individuals with respect to BMI across the different HbA1c levels.

There is a significant loss of skeletal muscle mass and an increase in BF% with increasing age; the term ‘sarcopenia’ relates to age-related decreases in muscle mass and strength. Low muscle mass and increased BF% are associated with a risk of developing metabolic disorders, including T2D.41 Because of lifestyle changes and longer life expectancy, the burden of T2D and sarcopenic obesity is projected to increase globally; both share common risk factors, such as ageing and general obesity.42 Individuals with T2D tend to develop sarcopenic obesity, which is likely to increase with age.43 A Japanese study reported that patients with diabetes had higher risk of sarcopenia than patients without diabetes. Additionally, elderly sarcopenic males had significantly lower BF% and a longer duration of T2D compared with non-sarcopenic males (p<0.01).44 Another recent study reported increased odds of sarcopenia with increased percentage of total fat in individuals with T2D compared with the control group (men: odds ratio [OR] 1.31, 95% CI 1.10–1.75; women: OR 1.18, 95% CI 1.03–1.43).45 Our study did not evaluate muscle mass and strength; however, we did find a strong association between an obese BF% and increasing age, and duration of diabetes.

Metformin monotherapy was the most commonly prescribed (97.9%) oral anti-diabetic drug in this study; however, some patients were receiving newer oral anti-diabetic drugs such as SGLT2is and DPP4is. The Research Society for the Study of Diabetes in India–Endocrine Society of India 2020 clinical practice recommendations for management of T2D in India suggest that lifestyle changes (including dietary modification, exercise and behavioural management) alongside pharmacotherapy and bariatric surgery are the most effective interventions for weight management in patients with T2D.46 The guidelines recommend novel therapeutic agents such as glucagon-like peptide (GLP)-1 agonists, DPP4is and SGLT2is as add-ons to metformin in obese patients with T2D. The pleiotropic effect of SGLT2is and GLP-1 agonists can facilitate weight management, particularly by reducing visceral fat.47,48 SGLT2is and GLP-1 agonists minimize weight gain when added to metformin and/or sulfonylurea, and the clinically meaningful body weight reductions can further contribute reduced HbA1c and systolic blood pressure.49,50 The co-administration of these novel oral anti-diabetic drugs that target complementary mechanisms represents an effective strategy for weight loss, with additional cardiorenal benefits among South Asian people.51

The Indian Phenotype Registry is a real-world registry based on data collected from routine clinical practice, with no follow-up visits. Hence, issues related to an observational registry, such as loss to follow-up and missing data, as well as the unavailability of zone-specific data, form some important limitations. Data on dyslipidaemia, such as HDL, LDL, total cholesterol and triglycerides, were not collected in this study. Although we assessed the correlation between HbA1c and BMI, the correlation between HbA1c and BF% was not investigated. Additionally, being a cross-sectional analysis, the study cannot affirm a causal association between obesity and other variables. However, this is one of the largest registries worldwide exploring IP characteristics. In India, the relationship between BMI and BF% has been investigated in region-specific prevalence studies, but with smaller sample sizes. Results from the IP registry can augment and substantiate the current evidence pool describing the Asian phenotype. The large sample size, with a representative population from diverse geographies and healthcare tiers of India, strengthen the results of the study.

Conclusion

The Indian Phenotype Registry is a pan-India cross-sectional registry that aims to generate nationwide data and provide clear insights about the phenotypic characteristics specific to Indian patients with T2D. Results from this study affirm the key characteristics of the IP of a low BMI with a high BF%. Additionally, the mean HbA1c levels were high, despite the majority of patients receiving anti-diabetic medications. Insights on the high BF distribution in Indian patients with T2D highlight the importance of effectively identifying risk factors (primordial prevention), diagnosing early (primary prevention) and aggressively managing obesity with intensive diet, exercise and therapy interventions to reduce complications and comorbidities (secondary prevention). These findings will guide therapeutic decisions on the choice of agents for glycaemic control, with preference for drugs that promote weight loss, such as SGLT2is and GLP-1 agonists, or are weight neutral, such as metformin, α-glucosidase inhibitors and DPP4is.47–50

Article Information:
Disclosure

Ranjini Sen is an employee of AstraZeneca Pharma India Ltd. Sanjay Kalra, Ambrish Mithal, Abdul Hamid Zargar, Bipin Sethi, Mala Dharmalingam and Sujoy Ghosh have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

The study was conducted at each site after receiving approval for the study protocol from the ethics committee and in accordance with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice, and Good Pharmacoepidemiology Practice guidelines. Written informed consent was received from all the participants involved in the study.

Review Process

Double-blind peer review

Authorship

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Correspondence

Sanjay Kalra, Department of Endocrinology, Bharti Hospital, Wazir Chand Colony, Kunjpura Road, Karnal, Haryana 132001, India. E: brideknl@gmail.com

Support

The Indian Phenotype Registry study was funded by AstraZeneca Pharma India Ltd.

Access

This article is freely accessible at touchENDOCRINOLOGY.com. © Touch Medical Media 2022

Acknowledgements

The authors would like to thank AstraZeneca Pharma India Ltd, Bangalore and Tech Observer India Pvt Ltd, the contract research organization for supervising the study, providing administrative support for the development of this manuscript. The authors would also like to thank Piyalee Pal from Labcorp Clinical Development Private Ltd for providing medical writing assistance in accordance with the GPP3 guidelines (http://www.ismpp.org/gpp3).

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received

2022-01-10

References

  1. Manne-Goehler J, Geldsetzer P, Agoudavi K, et al. Health system performance for people with diabetes in 28 low- and middle-income countries: A cross-sectional study of nationally representative surveys. PLoS Med. 2019;16:e1002751.
  2. International Diabetes Federation. IDF Diabetes Atlas, 9th edition 2019: South-east Asia. Available at: diabetesatlas.org/upload/resources/material/20191218_144626_sea_factsheet_en.pdf(accessed 4 June 2021).
  3. Vijayakumar G, Manghat S, Vijayakumar R, et al. Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: Results from a 10-year prospective cohort. BMC Public Health. 2019;19:140.
  4. Unnikrishnan R, Gupta PK, Mohan V. Diabetes in South Asians: Phenotype, clinical presentation, and natural history. Curr Diab Rep. 2018;18:30.
  5. Tandon N, Anjana RM, Mohan V, et al. The increasing burden of diabetes and variations among the states of India: The Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018;6:e1352–62.
  6. Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states of India: R esults from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5:585–96.
  7. Verma M, Das M, Sharma P, et al. Epidemiology of overweight and obesity in Indian adults – A secondary data analysis of the National Family Health Surveys. Diabetes Metab Syndr Reviews. 2021;15:102166.
  8. Ahirwar R, Mondal PR. Prevalence of obesity in India: A systematic review. Diabetes Metab Syndr. 2019;13:318–21.
  9. Luhar S, Timæus IM, Jones R, et al. Forecasting the prevalence of overweight and obesity in India to 2040. PLoS One. 2020;15:e0229438.
  10. Item F, Konrad D. Visceral fat and metabolic inflammation: The portal theory revisited. Obes Rev. 2012;13:30–9.
  11. Janochova K, Haluzik M, Buzga M. Visceral fat and insulin resistance–what we know? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163:19–27.
  12. Unnikrishnan R, Anjana RM, Mohan V. Diabetes in South Asians: Is the phenotype different? Diabetes. 2014;63:53–5.
  13. Mohan V, Sandeep S, Deepa R, et al. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217–30.
  14. Bakker LEH, Sleddering MA, Schoones JW, et al. Pathogenesis of type 2 diabetes in South Asians. Eur J Endocrinol. 2013;169:R99–114.
  15. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.
  16. Garg DK, Dutta MK. Body mass composition among underweight type 2 diabetes mellitus patients – A cross-sectional comparative study. Indian J Endocrino Metab. 2019;23:222.
  17. Kesavachandran CN, Bihari V, Mathur N. The normal range of body mass index with high body fat percentage among male residents of Lucknow city in north India. Indian J Med Res. 2012;135:72–7.
  18. Misra P, Singh AK, Archana S, et al. Relationship between body mass index and percentage of body fat, estimated by bio-electrical impedance among adult females in a rural community of North India: A cross-sectional study. J Postgrad Med. 2019;65:134–40.
  19. Secrets of Healthy Eating. BMI calculator India, body mass index chart for Asian men & women. Available at:
    https://secretsofhealthyeating.com/bmi-calculator-india.html(accessed 16 July 2021).
  20. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26:107–39.
  21. American Diabetes Association. (2) Classification and diagnosis of diabetes.Diabetes Care. 2015;38(Suppl. 1):S8–16.
  22. Deurenberg P, Deurenberg‐Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3:141–6.
  23. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2021;9:419–26.
  24. Bellary S, Paul O’Hare J, Raymond NT, et al. Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study – effect of ethnicity on risk. Current Med Res Opin. 2010;26:1873–9.
  25. Kurniawan LB, Bahrun U, Hatta M, et al. Body mass, total body fat percentage, and visceral fat level predict insulin resistance better than waist circumference and body mass index in healthy young male adults in Indonesia. J Clin Med. 2018;7:96.
  26. Bhopal RS. A four‐stage model explaining the higher risk of type 2 diabetes mellitus in South Asians compared with European populations. Diabet Med. 2013;30:35–42.
  27. Ranasinghe C, Gamage P, Katulanda P, et al. Relationship between body mass index (BMI) and body fat percentage, estimated by bioelectrical impedance, in a group of Sri Lankan adults: A cross sectional study. BMC Public Health. 2013;13:1–8.
  28. Deurenberg-Yap M, Schmidt G, van Staveren WA, et al. The paradox of low body mass index and high body fat percentage among Chinese, Malays and Indians in Singapore. Int J Obes Relat Metab Disord. 2000;24:1011–7.
  29. Kapoor N, Furler J, Paul TV, et al. Normal weight obesity: An under-recognized problem in individuals of South Asian descent. Clin Ther. 2019;41:1638–42.
  30. Kapoor N, Lotfaliany M, Sathish T, et al. Prevalence of normal weight obesity and its associated cardio-metabolic risk factors – results from the baseline data of the Kerala Diabetes Prevention Program (KDPP). PLoS One. 2020;15:e0237974.
  31. Kwon SK. Women are diagnosed with type 2 diabetes at higher body mass indices and older ages than men: Korea National Health and Nutrition Examination Survey 2007-2010. Diabetes Metab J. 2014;38:74–80
  32. Verma M, Rajput M, Sahoo SS, et al. Correlation between the percentage of body fat and surrogate indices of obesity among adult population in rural block of Haryana. J Family Med Prim Care. 2016;5:154–9.
  33. Saikia D, Ahmed SJ, Saikia H, et al. Body mass index and body fat percentage in assessing obesity: An analytical study among the adolescents of Dibrugarh, Assam. Indian J Public Health. 2018;62:277.
  34. Neel JV. Diabetes mellitus: A “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet. 1962;14:353–62.
  35. Chooi YC, Ding C, Chan Z, et al. Moderate weight loss improves body composition and metabolic function in metabolically unhealthy lean subjects. Obesity. 2018;26:1000–7.
  36. Chiu M, Austin PC, Manuel DG, et al. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011;34:1741–8.
  37. Bank IE, Gijsberts CM, Teng TH, et al. Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure. JACC Heart Fail. 2016;5:14–24.
  38. Nightingale CM, Rudnicka AR, Owen CG, et al. Influence of adiposity on insulin resistance and glycemia markers among UK children of South Asian, black African-Caribbean, and white European origin: Child heart and health study in England. Diabetes Care. 2013;36:1712–9.
  39. Sheth J, Shah A, Sheth F, et al. The association of dyslipidemia and obesity with glycated hemoglobin. Clin Diabetes Endocrinol. 2015;1:6.
  40. Park SK, Ryoo JH, Oh CM, et al. Longitudinally evaluated the relationship between body fat percentage and the risk for type 2 diabetes mellitus: Korean Genome and Epidemiology Study (KoGES). Eur J Endocrinol. 2018;178:513–21.
  41. Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057–72.
  42. Wang M, Tan Y, Shi Y, et al. Diabetes and sarcopenic obesity: Pathogenesis, diagnosis, and treatments. Front Endocrinol (Lausanne). 2020;11:568.
  43. Chen F, Xu S, Wang Y, et al. Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin. J Diabetes Res. 2020;2020:3950404.
  44. Fukuoka Y, Narita T, Fujita H, et al. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig. 2019;10:322–30.
  45. Pechmann LM, Jonasson TH, Canossa VS, et al. Sarcopenia in type 2 diabetes mellitus: A cross-sectional observational study. Int J Endocrinol. 2020;2020.
  46. Chawla R, Madhu SV, Makkar BM, et al. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020;24:1.
  47. Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7:e50117.
  48. Koike Y, Shirabe SI, Maeda H, et al. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Prac. 2019;149:140–6.
  49. Cefalu WT, Stenlöf K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–7.
  50. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis. JAMA. 2016;316:313–24.
  51. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79:219–30.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72